Introduction
============

Natural killer (NK) cells are granular lymphocytes found in peripheral blood, bone marrow, spleen, and lymph nodes.[@b1-tacg-9-039]--[@b4-tacg-9-039] In peripheral blood, NK cells comprise 15% of lymphocytes and can be grouped into four subtypes according to the surface expression and density of CD56 (neural cell-adhesion molecule) and CD16 (FcγIII receptor, the low-affinity receptor for IgG).[@b1-tacg-9-039]--[@b3-tacg-9-039],[@b5-tacg-9-039],[@b6-tacg-9-039] These phenotypes include CD56^bright^CD16^−/dim^, CD56^dim^CD16^bright^, CD56^dim^CD16^−^, and CD56^−^CD16^bright^.[@b1-tacg-9-039]--[@b3-tacg-9-039] Approximately 90% of NK cells in peripheral blood are CD56^dim^CD16^bright^, and CD56^bright^ comprise approximately 10%.[@b2-tacg-9-039]--[@b4-tacg-9-039],[@b7-tacg-9-039] NK cell cytotoxic activity requires a number of regulated processes to ensure apoptosis of the target cell.[@b8-tacg-9-039]

Though little is known about Ca^2+^ signaling in NK cells, it has been observed that the granule-dependent pathway of apoptosis is calcium-dependent, whereas the death receptor pathway is not.[@b9-tacg-9-039],[@b10-tacg-9-039] In apoptosis, lytic protein transport, exocytosis, and fusion have clearly shown calcium dependence.[@b11-tacg-9-039]--[@b13-tacg-9-039] Ca^2+^ is also required for the reorientation of microtubules and the actin skeleton, as well as activation of cytokine gene transcription.[@b13-tacg-9-039] Moreover, studies have demonstrated the relationship between calcium mobilization and the abrogation of degranulation in NK PLCγ2-deficient cells.[@b13-tacg-9-039]--[@b15-tacg-9-039]

Transient receptor potential (TRP) ion channels are expressed on almost all cells, and have a significant effect on physiological functions.[@b16-tacg-9-039] Dysregulation in TRPs has been associated with pathological conditions and diseases, such as cancer, skeletal abnormalities, pain syndrome, glomerulo-sclerosis, Olmsted syndrome, mucolipidosis, and polycystic kidney disease.[@b17-tacg-9-039]--[@b21-tacg-9-039] TRP ion channels are activated in the presence of irritants, inflammatory products, and xenobiotic toxins, and have an important role in Ca^2+^ signaling.

Acetylcholine (ACh) binds to two membrane proteins, namely the muscarinic receptor (mAChR) and nicotinic receptor (nAChR), of which there are multiple isoforms. ACh performs nonneuronal functions, termed the nonneuronal cholinergic system, comprising β-pancreatic cells, glial cells, lymphocytes, ocular lens cells, and brain vascular endothelium,[@b17-tacg-9-039]--[@b26-tacg-9-039] which is mediated through Ca^2+^ signaling. AChRs transmit activation signals in a variety of human tissues, including skeletal and smooth muscle, all preganglionic autonomic nerve fibers, postganglionic autonomic parasympathetic nerves, and in many locations throughout the central nervous system.[@b27-tacg-9-039]--[@b29-tacg-9-039]

Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) has an unknown etiology, and there is no specific diagnostic test. The illness is largely characterized by significant impairment in physical activity and debilitating fatigue, and can be accompanied by impairment in memory, cognition, and concentration, enhanced experience of muscle and joint pain, headaches, sore throat, and tender lymph nodes. It is further associated with dysregulation of the gastrointestinal, cardiovascular, and immune systems.[@b30-tacg-9-039]--[@b42-tacg-9-039] Importantly, NK cell dysfunction, in particular reduced NK cell cytotoxic activity, is a common finding in ME/CFS patients.[@b32-tacg-9-039]--[@b36-tacg-9-039],[@b39-tacg-9-039],[@b43-tacg-9-039] We have previously identified single-nucleotide polymorphisms (SNPs) in TRP ion channel genes and AChR genes, namely *TRPM3*, *TRPA1*, *TRPC4*,[@b44-tacg-9-039] *CHRM3*, *CHRNA10*, *CHRNA5*, and *CHRNA2* in peripheral blood mononuclear cells from ME/CFS patients.[@b44-tacg-9-039] These SNP anomalies in genes for TRP ion channels and AChRs may produce altered receptor proteins, potentially changing TRP ion channel and AChR structures and also functions.

The aim of the present study was to determine NK cytotoxic activity, as well as whether SNPs and their genotypes were present in TRP ion channel and AChR genes in isolated NK cells from ME/CFS patients.

Subjects and methods
====================

Subjects
--------

ME/CFS patients were defined in accordance with the 1994 Centers for Disease Control and Prevention criteria for CFS.[@b45-tacg-9-039] A total of 39 ME/CFS patients and 30 unfatigued controls recruited for this study reported no medical history, symptoms of prolonged fatigue, or illness of any kind, and were screened for major disease according to routine pathology tests. All participants provided informed written consent and all samples were deidentified for the purposes of analysis. This study was approved by the Griffith University Human Research Ethics Committee (MSC22/12HREC).

Sample preparation and measurements
-----------------------------------

A total volume of 80 mL of blood was collected from the antecubital vein of all participants into lithium-heparinized and ethylenediaminetetraacetic acid (EDTA) collection tubes between 9 am and 11 am. Routine blood samples were analyzed from 10 mL of blood within 6 hours of collection and analyzed for red blood cell counts, lymphocytes, granulocytes, and monocytes using an automated cell counter (ACT differential analyzer; Beckman Coulter, Brea, CA, USA) ([Table 1](#t1-tacg-9-039){ref-type="table"}).

NK cell isolation
-----------------

NK cells were isolated from 40 mL of whole blood using Ficoll-Paque (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and performed using an NK isolation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions. NK cell purity was measured after staining with CD56 and CD3 antibodies and analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Diego, CA, USA). NK cells were reported as the percentage of positive CD56^+^CD3^−^ cells. Isolated NK cells were either used to measure NK cell cytotoxicity activity or snap-frozen in liquid nitrogen and stored at −80°C until further SNP assessment.

NK cell cytotoxicity
--------------------

NK cytotoxic activity was conducted as previously described.[@b36-tacg-9-039],[@b39-tacg-9-039] Briefly, following NK lymphocyte isolation using density-gradient centrifugation and labeling with 0.4% PKH-26 (Sigma-Aldrich, St Louis, MO, USA), NK cells were incubated with K562 cells for 4 hours at 37°C in 95% air, 5% CO~2~ at an effector to target (E:T) ratio of 25 (NK cells):1 (K562). An E:T ratio of 25:1 has been previously shown by us and other researchers to be the most optimal ratio for assessing cytotoxic activity.[@b36-tacg-9-039],[@b39-tacg-9-039] NK cell lysis activity was determined after incubating K562 cells for 4 hours, and was calculated to determine induced tumor-cell death or apoptosis.[@b1-tacg-9-039] FACSCalibur flow cytometry using annexin V--fluorescein isothiocyanate and 7-aminoactinomycin reagents (BD Biosciences) was employed. NK cytotoxic activity was performed within 2--4 hours upon receipt of all blood samples.

DNA extraction
--------------

A volume of 40 mL was collected into EDTA tubes for SNP analysis. Genomic DNA was extracted from isolated NK cell samples using the Qiagen DNA blood minikit as per manufacturer's instructions (Qiagen NV, Venlo, the Netherlands). SNP-genotyping studies were performed as previously described.[@b44-tacg-9-039],[@b46-tacg-9-039]

SNP analysis
------------

A total of 678 SNPs from isolated NK cells were examined for 21 mammalian TRP ion channel genes (*TRPA1*, *TRPC1*, *TRPC2*, *TRPC3*, *TRPC4*, *TRPC6*, *TRPC7*, *TRPM1*, *TRPM2*, *TRPM3*, *TRPM4*, *TRPM5*, *TRPM6*, *TRPM7*, *TRPM8*, *TRPV1*, *TRPV2*, *TRPV3*, *TRPV4*, *TRPV5*, and *TRPV6*) and for nine mammalian AChR genes (muscarinic M1, M2, M3, M4, M5, nicotinic α2, α3, α5, α7, α10, and ε), and were examined using a MassArray iPlex Gold assay (Sequenom Inc, San Diego, CA, USA). Quality and quantity of the DNA extracted was determined by a NanoDrop, where approximately 2 µg of genomic DNA was used to perform the SNP analysis. SNP analysis was performed as previously described.[@b44-tacg-9-039],[@b46-tacg-9-039] Briefly, the MassArray (matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry platform) was employed to discriminate alleles based on single-base extension of an extension primer of known mass that was designed to attach directly next to the SNP site of interest. Custom multiplexed wells were designed in silico using Agena's Assay Design Suite. The designed multiplexes were then built using custom synthesized oligonucleotides that were pooled together for sample processing. The iPlex Gold chemistry utilized two multiplexed oligopools for each genotyping well. These were pooled and balanced prior to running against DNA samples. First, a multiplexed polymerase chain reaction (PCR) pool was utilized to generate short amplicons that included all the genomic markers of interest in that particular well. After PCR and cleanup steps were undertaken, a secondary PCR "extension" step was undertaken, utilizing pools of extension primers that were designed to attach directly next to the SNP sites of interest. A termination mix was added to the extension phase, which allowed these extension primers to be extended by a single base only. As the molecular weight of the extension primer was known, discrimination of the allele was able to be measured using the peak heights of the unextended primer (UEP) and this primer plus the possible single-base extension possibilities for the SNP.

TRP ion channel and AChR SNP assays
-----------------------------------

For each SNP, two PCR primers and one extension primer were created using the Assay Designer (Sequenom) according to the manufacturer's instructions. A tag was added to the 5′-end of the sequence for each primer. This was done to increase their mass so they were not detected by MassArray when analyzing the extension primers. DNA was amplified via PCR under the following conditions: 94°C for 2 minutes, 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 1 minute. Amplification products were then treated with shrimp alkaline phosphatase at 37°C for 40 minutes, 85°C for 5 minutes' reaction, and a final incubation at 4°C. Extension primers were optimized to control the signal-to-noise ratio, where UEPs are examined on the SpectroChip and evaluated in Typer 4.0 to enable the division into low-mass UEP, medium-mass UEP, and high-mass UEP. To perform the iPlex extension reaction, a mixture containing iPlex Gold reaction was prepared using iPlex Gold Buffer Plus, iPlex termination mix, iPlex enzyme, and primer mix. The iPlex reaction was cycled at an initial denaturation of 94°C for 30 seconds, annealing at 52°C for 5 minutes, extension at 80°C for 5 minutes (five cycles of annealing and extension were performed, but the whole reaction was performed in 40 cycles), and extension again at 72°C for 3 minutes. Resin beads were used to rinse all iPlex Gold reaction products. Following the iPlex Gold reaction, spectrometry was performed using the MassArray mass spectrometer, and the data generated were analyzed using the TyperAnalyzer software.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS software version 22 (IBM Corporation, Armonk, NY, USA). The experimental data represented in this study are reported as mean ± standard error of the mean, while all the clinical data are reported as mean ± standard deviation. Comparative assessments among participants (ME/CFS and unfatigued controls) were performed with analysis of variance, and the criterion for significance was set at *P*\<0.05.

The Plink version 1.07 (<http://pngu.mgh.harvard.edu/purcell/plink>) whole-genome-analysis tool set was used to determine associations between the ME/CFS patients and the unfatigued control group. A two-column *χ*^2^ test was used to examine differences where *P*\<0.05 was determined to be significant, and the resulting variants and their consequences can be found in [Table 2](#t2-tacg-9-039){ref-type="table"} for TRP and AChR, respectively. Further genotype analysis for differences between CFS and the unfatigued group was also completed according to a two-column *χ*^2^ test with significance set at *P*\<0.05. Analyses were performed at the Australian Genome Research Facility Ltd, Walter and Eliza Hall Institute, Melbourne, Australia.

Results
=======

Participants
------------

There were 39 CFS patients (age 51.69±2 years), of which 71.79% were females. There were 30 unfatigued controls (age 47.60±2.39 years), of which 56.67% were females. All participants in both groups were of European descent and were residents of Australia at the time of blood collection. There were no significant changes in white blood-cell counts between ME/CFS patients and the unfatigued control group. [Table 1](#t1-tacg-9-039){ref-type="table"} outlines participants' characteristics.

NK cell purity
--------------

There was no significant difference between groups for levels of NK purity. [Figure 1](#f1-tacg-9-039){ref-type="fig"} outlines the high levels of purity (\>93%) of NK cells following isolation and enrichment.

NK cell cytotoxic activity
--------------------------

There was a significant difference for NK cytotoxic activity between groups at the E:T ratio of 25:1. ME/CFS patients had a significant reduction in NK percentage lysis of target cells (17%±4.68%) compared with the control group (31%±6.78%) ([Figure 2](#f2-tacg-9-039){ref-type="fig"}).

SNP analysis
------------

Of 678 SNPs identified in TRP ion channel and AChR genes from isolated NK cells, there were eleven SNPs for TRP ion channel genes (*TRPC4*, *TRPC2*, *TRPM3*, and *TRPM8*) that were significantly associated in the ME/CFS group. Five of these SNPs were associated with *TRPM3* (rs6560200, *P*=0.01; rs1106948, *P*=0.01; rs12350232, *P*=0.018; rs11142822, *P*=0.021; rs1891301, *P*=0.024) while the remainder were associated with *TRPM8* (rs17865678, *P*=0; rs1156320, *P*=0.001), *TRPC2* (rs7108612, *P*=0.034; rs6578398, *P*=0.0334), and *TRPC4* (rs2985167, *P*=0.001; rs655207, *P*=0.018).

Fourteen SNPs were associated with nicotinic and muscarinic AChR genes, where six were *CHRNA3* (rs12914385, *P*=0.015; rs2869546, *P*=0.021; rs951266, *P*=0.033; rs4243084, *P*=0.040; rs3743075, *P*=0.041; rs3743074, *P*=0.041), while the remainder were associated with *CHRNA2* (rs891398, *P*=0.017; rs2741343, *P*=0.019), *CHRNB4* (rs12441088, *P*=0.009), *CHRNA5* (rs7180002, *P*=0.043), and *CHRNE* (rs33970119, *P*=0.041). [Table 2](#t2-tacg-9-039){ref-type="table"} presents the SNPs for TRP ion channel and AChR genes isolated from NK cells.

Genotype analysis
-----------------

There were 16 genotypes identified from SNPs that were reported significant for *TRPM3* (n=5), *TRPM8* (n=2), *TRPC4* (n=3), *TRPC2* (n=1), *CHRNE* (n=1), *CHRNA2* (n=2), *CHRNA3* (n=1), and *CHRNB4* (n=1). Of the significant SNPs identified in [Table 2](#t2-tacg-9-039){ref-type="table"}, we further analyzed whether genotypes differed between groups. [Table 3](#t3-tacg-9-039){ref-type="table"} presents the genotypes for SNPs in TRP and AChR genes from isolated NK cells that were reported as statistically significant between groups. The odds ratios for specific genotypes for SNPs in TRP and AChR genes from isolated NK cells ranged between 3.13 and 11.39 for ME/CFS compared with the unfatigued control group.

Discussion
==========

Reduced NK cell cytotoxic activity has previously been reported in ME/CFS, and the current investigation supports those findings. The current investigation reports novel findings for a number of SNPs in genes for AChR and TRP variants and genotypes from isolated NK cells from ME/CFS patients. A further novel finding from this investigation is the identification of SNPs in *TRPM3* and *TRPM8* from isolated NK cells, suggesting *TRPM3* and *TRPM8* receptors are located on NK cells.

Our investigation reports a significant reduction in NK lysis in ME/CFS patients compared with the unfatigued controls. The role of TRP ion channels in Ca^2+^ signaling and innate and adaptive immune cells is being increasingly documented.[@b47-tacg-9-039] TRPs have been reported to express TRP cation channel and TRP melastatin subfamilies, mainly *TRPC1*, *TRPC3*, *TRPC5*, *TRPM2*, *TRPM4*, and *TRPM7*.[@b48-tacg-9-039] These channels are nonselective and permeable to calcium. In NK cells, Ca^2+^ plays a key role in lytic granule fusion,[@b11-tacg-9-039],[@b12-tacg-9-039],[@b49-tacg-9-039] as well as ensuring lytic granules mobilize to the immune synapse to release perforin and granzymes to kill target cells.[@b11-tacg-9-039],[@b12-tacg-9-039],[@b49-tacg-9-039] The Rho GTPase Miro provides a link between the mitochondria and the microtubules, where it mediates the Ca^2+^-dependent arrest of mitochondrial motility.[@b50-tacg-9-039] As Miro modifies mitochondrial polarization, it may also alter lytic granule trans port to the immune synapse as well as lytic function, due to modulation by cytosolic Ca^2+^ concentration through TRP melastatin and AChR genes. Clearly, mitochondria play a key role in NK cell function. A recent discovery that mitochondria express a range of AChR subtypes, including nicotinic α3, although differentially expressed according to tissue type,[@b51-tacg-9-039] suggests that nAChRs may impact mitochondrial function and regulate oxidant stress. Interestingly, we have previously reported a significant decrease in respiratory bust function of neutrophils from ME/CFS patients.[@b34-tacg-9-039]

*TRPM2* and *TRPM3* mobilize Ca^2+^, where the latter has been shown to mediate Ca^2+^ signaling for cytolytic granule polarization and degranulation.[@b52-tacg-9-039] Further, NK cells treated with an adenosine diphosphate-ribose antagonist had reduced tumor-induced granule polarization, degranulation, granzyme B secretion, and cytotoxicity of NK cells. Interestingly, similar findings for NK cell functions have been reported from previous ME/CFS research,[@b32-tacg-9-039]--[@b36-tacg-9-039] potentially suggesting that the genotype changes reported in this present study for *TRPM3* may also play a similar role in cytolytic granule polarization and degranulation.

Of the 678 SNPs examined, eleven variants for TRP ion channels and 14 variants for AChRs were found to be significantly associated with ME/CFS patients compared with the unfatigued controls. The variant TRP SNPs were located in the gene sequence of two of the canonical TRP ion channels (*TRPC2* and *TRPC4*) and two melastatin TRP ion channels (*TRPM3* and *TRPM8*). We also report variant SNPs in genes for two of the *CHRM3* receptors, two *CHRM1* receptors, six *CHRNA3* receptors, three *CHRNA2* receptors, and one *CHRNA5* receptor, as well as one *CHRNB4* receptor and one *CHRNE* receptor.

Our current research reports significant SNP associations of genotypes for AChRs in isolated NK cells from ME/CFS patients. Lymphocytes expressed both muscarinic and nicotinic AChRs, where T- and B-cells and monocytes expressed all five subtypes of mAChRs (M1--M5), while nAChRs were found for α2--α7, α9, α10, β2, and β10 subunits.[@b53-tacg-9-039]--[@b56-tacg-9-039] Lymphocytes constitute a cholinergic system that is independent of cholinergic nerves, resulting in the regulation of immune function.[@b53-tacg-9-039],[@b54-tacg-9-039] AChR agonists have been shown to enhance lymphocyte cytotoxicity and increase their intracellular cyclic guanosine monophosphate and inositol-1,4,5-triphosphate,[@b53-tacg-9-039],[@b57-tacg-9-039] suggesting the lymphocytic cholinergic system is involved in the regulation of immune function via AChRs coupled to PLC via changes in Ca^2+^.[@b58-tacg-9-039]--[@b63-tacg-9-039] Previous research has highlighted the importance of variants in affecting gene transcripts by causing alternative splicing, resulting in anomalies in messenger RNA and translation products.[@b64-tacg-9-039] We have also identified SNPs and genotype in *CHRNE* in ME/CFS patients. Interestingly, this SNP is located in the 3′-untranslated region, which is a binding site for regulatory proteins as well as microRNAs (miRNAs).[@b65-tacg-9-039] Binding to specific sites within the 3′-untranslated region, miRNAs can decrease gene expression of various messenger RNAs by either inhibiting translation or directly causing degradation of the transcript. Our previous research has found significant differences in NK cytotoxic activity, as well as in miRNAs from isolated NK cells from ME/CFS patients.[@b32-tacg-9-039]

Previous investigations have suggested that alternate splicing in the coding and also in the noncoding sequences may have significant unexpected outcomes on the splicing mechanism of the gene transcripts.[@b64-tacg-9-039],[@b66-tacg-9-039] Splicing genetic variants located in the exons, introns, and the assembly of the spliceosome all contribute to the splicing mechanism for the correct coding of a protein sequence. Moreover, silencers and enhancers located either in the exons or introns are integral in recognition of the correct exon sequence.[@b67-tacg-9-039] Importantly, introns are able to generate active spliceosomes, giving rise to alternative splicing events.[@b68-tacg-9-039],[@b69-tacg-9-039] Gene 80036 (*TRPM3*) is associated with calcium entry and calcium-store depletion via different isoforms that have been identified through alternative splicing.[@b70-tacg-9-039] A region that is indispensable for channel function is an 18-amino acid-residue region whose absence renders the channels functionally unable to mediate calcium entry, and is found devoid in a *TRPM3* variant.[@b71-tacg-9-039] Coexpression of these *TRPM3* ICF variants with functional *TRPM3* ion channels additionally shows impaired calcium mobilization.[@b71-tacg-9-039] As *TRPM3* ICF variants show ubiquitous expression in many tissues and cell types and constitute 15% of all *TRPM3* isoforms, expression on NK cells may provide a potential explanation for reduced cytotoxic activity in ME/CFS patients. Particular splice variants, such as TRPM3α1, may potentially be favored, culminating in a diminished NK cell cytotoxic response and heat detection, including dysregulation of thermoregulatory responses, nociception, and transmission of pain, such as central and peripheral pain perception. Moreover, *TRPM8* has also been identified to be activated by cold and noxious stimuli,[@b72-tacg-9-039]--[@b74-tacg-9-039] suggesting that the genotype changes reported in this investigation align with the clinical presentation of thermoregulatory responses, nociception, and transmission of central and peripheral pain perception seen in ME/CFS patients.[@b75-tacg-9-039]

Our results suggest that SNP variants and genotypes reported in NK cells may not be exclusive to this immune-cell type. AChRs and TRP ion channel receptors are located ubiquitously on multiple cell types and control other functions in body systems. Ca^2+^ signaling in the context of TRP ion channels and AChR function is vital for the function of the central nervous system, and there is wide variety in the nicotinic receptors expressed in animal and human immune cells.[@b56-tacg-9-039] Of note, nAChRs are reported to be involved in arousal, sleep, and fatigue, as well as those functions that are responsible for processing of pain, memory, and cognition, all of which are clinical symptoms reported in ME/CFS patients.[@b76-tacg-9-039]--[@b78-tacg-9-039]

Conclusion
==========

In this study, we identified, for the first time, SNPs in genes for TRPM3 and TRPM8 ion channels on isolated NK cells. We also identified numerous SNPs of nAChRs along with other TRP channels on isolated NK cells, which may explain the important role of the nonneuronal ACh system in NK cell function. Anomalies in genotypes for TRP ion channels and AChRs suggest that altered calcium would be an important functional consequence not only for NK cells but also depending upon tissue type, susceptibility, or predisposition to ME/CFS.
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![NK cell purity.\
**Notes:** The purity of NK cells represents minimal contamination from other cell types. Data shown for ME/CFS (n=38), and unfatigued controls (n=30), and presented as mean ± standard error of mean.\
**Abbreviations:** NK, natural killer; ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome.](tacg-9-039Fig1){#f1-tacg-9-039}

![Reduced NK cytotoxic activity in CFS/ME.\
**Notes:** In vivo assessment of NK (cytotoxic activity) of tumor-cell lines K562 in ME/CFS (n=39) and unfatigued controls (n=30). Lytic activity represented by percentage lysis of target cells on the *y*-axis. Data presented as mean ± standard error of mean. \**P*\<0.05.\
**Abbreviations:** NK, natural killer; ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome.](tacg-9-039Fig2){#f2-tacg-9-039}

###### 

Participant characteristics for ME/CFS and unfatigued controls

  Variable                       ME/CFS, n=39   Unfatigued controls, n=30   *P*-value
  ------------------------------ -------------- --------------------------- -----------
  Sex (% female)                 71.79%         56.67%                      0.228
  Mean age (years)               51.69±2        47.6±2.39                   0.191
  Hemoglobin (g/L)               136.05±2.07    138.8±2.24                  0.375
  Hematocrit (%)                 0.41±0.01      0.41±0.01                   0.702
  Red-cell count (×10^12^/L)     4.54±0.07      4.58±0.08                   0.697
  Mean corpuscular volume (fL)   89.97±0.55     90.07±0.7                   0.917
  White-cell count (×10^9^/L)    5.95±0.26      6.38±0.31                   0.747
  Neutrophils (×10^9^/L)         3.53±0.19      3.96±0.26                   0.173
  Lymphocytes (×10^9^/L)         1.91±0.1       1.97±0.08                   0.64
  Monocytes (×10^9^/L)           0.34±0.02      0.32±0.02                   0.41
  Eosinophils (×10^9^/L)         0.33±0.18      0.37±0.23                   0.892
  Basophils (×10^9^/L)           0.20±0.18      0.02±0                      0.385
  Platelets (×10^9^/L)           262.56±8.41    256.79±9.58                 0.653

**Note:** Data presented as mean ± standard deviation.

**Abbreviations:** ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome.

###### 

Analysis of frequency, distribution, and significance of SNPs in genes for TRP ion channels and AChRs in ME/CFS patients and unfatigued controls in rank order of significance

  Gene       CL   SNP          BPs                    A~1~   FM        FC        A~2~   *χ*^2^   OR       *P*-value
  ---------- ---- ------------ ---------------------- ------ --------- --------- ------ -------- -------- -----------
  *TRPM8*    2    rs17865678   2.34[@b8-tacg-9-039]   A      0.4595    0.1667    G      12.88    4.25     0.000332
  *TRPM8*    2    rs11563204   2.34[@b8-tacg-9-039]   A      0.3553    0.1167    G      10.18    4.172    0.00142
  *CHRNB4*   15   rs12441088   78,635,922             G      0.1795    0.3793    T      6.824    0.358    0.008993
  *TRPC4*    13   rs2985167    37,656,405             G      0.2821    0.5       A      6.742    0.3929   0.009418
  *TRPM3*    9    rs6560200    71,365,306             T      0.3974    0.6207    C      6.633    0.4031   0.01001
  *TRPM3*    9    rs1106948    71,402,258             C      0.3974    0.6167    T      6.521    0.41     0.01066
  *TRPM8*    2    rs6758653    2.34[@b8-tacg-9-039]   A      0.2436    0.45      G      6.502    0.3936   0.01078
  *CHRNA3*   15   rs12914385   78,606,381             T      0.4872    0.2833    C      5.879    2.403    0.01532
  *CHRNA2*   8    rs891398     27,467,305             C      0.5526    0.3448    T      5.714    2.347    0.01683
  *TRPM3*    9    rs12350232   71,417,232             G      0.3974    0.6       T      5.571    0.4397   0.01826
  *CHRNA2*   8    rs2741343    27,468,610             C      0.5526    0.35      T      5.537    2.294    0.01862
  *TRPM3*    9    rs11142822   71,427,327             T      0.03846   0.15      G      5.314    0.2267   0.02115
  *CHRNA3*   15   rs2869546    78,615,003             C      0.2763    0.4667    T      5.271    0.4364   0.02168
  *TRPM3*    9    rs1891301    71,403,580             T      0.5769    0.3833    C      5.085    2.194    0.02414
  *CHRNA3*   15   rs951266     78,586,199             T      0.4359    0.2586    C      4.536    2.215    0.03319
  *TRPC2*    11   rs7108612    3,628,856              T      0.1923    0.06667   G      4.509    3.333    0.03372
  *TRPC2*    11   rs6578398    3,616,831              A      0.3462    0.1833    G      4.506    2.358    0.03378
  *CHRM1*    11   rs6578398    62,920,797             A      0.2436    0.1034    G      4.354    2.791    0.03691
  *CHRM3*    1    rs4620530    2.4[@b8-tacg-9-039]    T      0.4744    0.3       G      4.301    2.106    0.03809
  *CHRM1*    11   rs11823728   62,909,330             T      0.05263   0.1607    C      4.242    0.2901   0.03943
  *CHRNA3*   15   rs4243084    78,619,330             G      0.4359    0.2667    C      4.204    2.125    0.04034
  *CHRNA3*   15   rs3743075    78,617,110             A      0.2821    0.45      G      4.177    0.4802   0.04097
  *CHRNA3*   15   rs3743074    78,617,138             C      0.2821    0.45      T      4.177    0.4802   0.04097
  *CHRNE*    17   rs33970119   4,901,607              A      0.03846   0.1333    G      4.161    0.26     0.04136
  *CHRNA5*   15   rs7180002    78,581,651             T      0.4342    0.2667    A      4.084    2.11     0.0433

**Notes:** SNPs of 39 CFS/ME patients and 30 unfatigued controls. Data presented all *P*\<0.05.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; TRP, transient receptor potential; AChRs, acetylcholine receptors; ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome; CL, chromosome location; BPs, base pairs; FM, frequency of A~1~/A~2~ allele in ME/CFS cases; FC, frequency of A~1~/A~2~ allele in controls; OR, odds ratio.

###### 

Analysis of genotype, ORs, and significance of SNPs in genes for TRP ion channels and AChRs in ME/CFS patients and unfatigued controls in rank order of significance

  Gene       CL   SNP          Genotype   ME/CFS, n (%)   Unfatigued controls, n (%)   *χ*^2^   OR      *P*-value
  ---------- ---- ------------ ---------- --------------- ---------------------------- -------- ------- -----------
  *TRPM8*    2    rs11563204   GA         23 (82.1)       5 (17.9)                     12.59    7.19    0
  *CHRNA2*   8    rs891398     CC         11 (91.7)       1 (8.3)                      7.31     11.39   0.007
  *CHRNA2*   8    rs2741343    CC         11 (91.7)       1 (8.3)                      7.3      11.39   0.007
  *TRPC4*    13   rs2985167    AA         20 (76.9)       6 (23.1)                     7.07     4.21    0.008
  *TRPM3*    9    rs6560200    CC         15 (83.3)       3 (16.7)                     7.12     5.63    0.008
  *TRPC4*    13   rs1570612    GG         30 (68.2)       14 (31.8)                    6.72     3.81    0.01
  *CHRNB4*   15   rs12441088   TT         25 (71.4)       10 (28.6)                    6.42     3.57    0.011
  *TRPM8*    2    rs17865678   AG         22 (73.3)       8 (26.7)                     6.1      3.56    0.013
  *TRPC4*    13   rs655207     GG         12 (85.7)       2 (14.3)                     6.09     6.22    0.014
  *CHRNA3*   15   rs12914385   TT         12 (85.7)       2 (14.3)                     6.09     6.22    0.014
  *TRPM3*    9    rs11142822   GG         36 (63.2)       21 (36.8)                    5.87     5.14    0.015
  *TRPM3*    9    rs1106948    TT         15 (78.9)       4 (21.1)                     5.37     4.06    0.021
  *TRPC2*    11   rs7108612    GT         15 (78.9)       4 (21.1)                     5.37     4.06    0.021
  *CHRNE*    17   rs33970119   GG         36 (62.1)       22 (37.9)                    4.56     4.36    0.033
  *TRPM3*    9    rs1891301    TT         14 (77.8)       4 (22.2)                     4.48     3.64    0.034
  *TRPM3*    9    rs12350232   TT         15 (75)         5 (25)                       3.91     3.13    0.048

**Notes:** Genotypes from 39 ME/CFS patients and 30 unfatigued controls. Data presented all *P*\<0.05; *df*=1 for basic allelic test.

**Abbreviations:** ORs, odds ratios; SNPs, single-nucleotide polymorphisms; TRP, transient receptor potential; AChRs, acetylcholine receptors; ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome; CL, chromosome location.
